US FDA's Califf On Real-World Evidence: 'Use It For The Right Purposes'
This article was originally published in SRA
Executive Summary
Randomized clinical trials have long been extolled as the gold standard for establishing drug efficacy and safety. However, US Food and Drug Administration Commissioner Robert Califf has his sights set on increased use of another type of research for informing regulatory decision-making: randomized clinical practice studies.
You may also be interested in...
US FDA Invites Randomized Trial Designs With Real-World Elements
Agency is eager to engage with sponsors on ‘well thought-out proposals' to include real-world data sources in randomized studies, Office of New Drugs director Peter Stein says but adds that believability and robustness of the data are the agency’s primary concern.
Postmarketing Safety Gets Closer Focus In Latest US FDA Drugs Center Reorganization
Division of Mitigation Assessment and Medication Error Surveillance will be established within the Office of Surveillance and Epidemiology, a change aimed at strengthening postmarketing oversight of opioids and other drugs; new Office of Safety and Clinical Evaluation will be created in Office of Generic Drugs, where Orange Book staff also will get their own division.
‘Frontline’ Essential Workers, Persons 75 Years And Older Prioritized For Second Phase Of COVID Vaccination
Essential workers who cannot work remotely and have high levels of interaction with the public, and individuals ≥75 years old, should get vaccinated ahead of those 65-74 years old and those with comorbid conditions, CDC Advisory Committee on Immunization Practices recommends.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: